In 2022, over 600,000 people across the world were diagnosed with bladder cancer, a 7.1% increase from 2020, putting their ...

VMPL Chennai Tamil Nadu [India] December 23 Kauvery Hospital Vadapalani a leading healthcare institution in Chennai has ...

Treatment with UGN-102 has shown promise as a non-surgical alternative when compared with a surgical approach for certain ...

The first target for this plasmid is non-muscle invasive bladder cancer (NMIBC), which is currently managed primarily with ...

ImmunityBio is conducting trials of Anktiva in various cancers, including NSCLC and ovarian cancer. Click here to read an analysis of IBRX stock now.

Although the use of intravesical immunotherapy for reducing tumor progression or as maintenance therapy is controversial, bacillus Calmette–Guérin has demonstrated significant benefit for tumor ...

Associated Medical Professionals of NY, Urology of Indiana and Central Ohio Urology Group are the latest three US-based study sites for clinical research of Theralase®'s bladder cancer treatment ...

(UroToday.com) The 2024 SUO annual meeting included a session on BCG unresponsive non muscle invasive bladder cancer (NMIBC), ...

Shares of Protara Therapeutics TARA rallied 70% on Wednesday after the company announced compelling results from the ...

Protara Therapeutics reports promising Phase 2 results for TARA-002 in bladder cancer patients, highlighting high response rates and strong safety data.

The trial is assessing intravesical TARA-002, the Company's investigational cell-based therapy, in high-risk Non-Muscle ...

Bladder cancer ranks as the 10th most commonly diagnosed cancer globally, affecting both men and women. Approximately 75% of patients are initially diagnosed with non-muscle invasive bladder cancer ...